Acanthus Pharma - LipidsALC-0315

ALC-0315

Catalog No: APS-LP-CAT-01
CAS No: 2036272-55-4
Molecular Formula: C₄₈H₉₅NO₅
Molecular Weight: 766.29
Type: Cationic/Ionizable
Purity: > 98 % by HPLC-CAD
Storage: -20 degrees
Solubility: Ethanol, DMSO, DMF
IUPAC Name: [(4-Hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)
SDS: Available
Grade: R & D or GMP

Don’t see a quantity you are interested in?

Click below to fill out a webform & we will get back to you in 48 hrs.!

Working Together. Smarter and Faster.

[1] Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-975. DOI: https://doi.org/10.1016/j.jconrel.2012.03.020

[2] Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni, Rein Verbeke, Gideon Kersten, Wim Jiskoot, Daan J.A. Crommelin. (2021) mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability, International Journal of Pharmaceutics, 601, 120586. DOI: https://doi.org/10.1016/j.ijpharm.2021.120586

[3] Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161-177. DOI: https://doi.org/10.1016/s0939-6411(00)00087-4

[4] Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419-436. DOI: https://doi.org/10.2165/00003088-200342050-00002

[5] Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, Khar RK. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech. 2011 Jun;12(2):712-22. DOI: https://doi.org/10.1208%2Fs12249-011-9636-8

[6] Ilyas U, Asif M, Wang M, Altaf R, Zafar H, Faran Ashraf Baig MM, Paiva-Santos AC, Abbas M. Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes. Front Pharmacol. 2022 Jul 12;13:934156. DOI: https://doi.org/10.3389%2Ffphar.2022.934156